- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (236)
- Breast Cancer (714)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (158)
- Colon Cancer (166)
- Colorectal Cancer (106)
- Endocrine Tumor (4)
- Esophageal Cancer (40)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (2)
- Kidney Cancer (124)
- Leukemia (352)
- Liver Cancer (50)
- Lung Cancer (292)
- Lymphoma (286)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (102)
- Myelodysplastic Syndrome (64)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (172)
- Pancreatic Cancer (172)
- Parathyroid Disease (2)
- Penile Cancer (16)
- Pituitary Tumor (6)
- Prostate Cancer (146)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (54)
- Spinal Tumor (12)
- Stomach Cancer (58)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (32)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (8)
- Advance Directives (4)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (20)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (220)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (126)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (114)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (862)
- Research (402)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (598)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (406)
- Survivorship (320)
- Symptoms (178)
- Treatment (1762)
Metastatic melanoma survivor: Why not me?
BY Bob Wilkes
4 minute read | Published October 09, 2020
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on October 09, 2020
In 2012, my dermatologist in South Carolina noticed a bump on my cheek. A biopsy showed that I had stage IV melanoma.
We’d heard immunotherapy had proven successful in treating certain types of melanoma. But because I had an autoimmune disease, I was not eligible for this treatment at the time. Researchers still needed to figure out how to safely administer immunotherapy to patients with autoimmune conditions.
So, I had the cancerous tissue removed through Mohs surgery. This type of surgery uses precise measurement techniques that leave healthy tissue intact. My wife, Pam, and I felt positive after my successful surgery.
By 2014, I learned the cancer had returned and metastasized to both my lungs. My daughter had recently gotten engaged, and it was hard to hear I may not live until her wedding. I decided not to give up, so I sought another opinion.
My metastatic melanoma diagnosis and treatment
My wife and I came to MD Anderson, where we met with melanoma experts in the Melanoma and Skin Center. They referred me to thoracic surgeon Dr. Wayne Hofstetter. I underwent two thoracotomies with lung resections -- one on each lung. I was overjoyed to recover in time to walk my daughter down the aisle.
During a routine scan in 2016, I found out that more tumors had appeared. This time, radiation oncologist Dr. Quynh-Nhu Nguyen performed stereotactic body radiation therapy (SBRT). This eliminated the tumors. I was in remission once again.
But in 2018, I started having difficulty swallowing certain foods. My gastroenterologist in South Carolina performed an endoscopic ultrasound. The results showed a tumor on a lymph node next to my esophagus. After sending the results to MD Anderson, we made plans to return to Houston. Dr. Hofstetter removed the tumors through a robotic surgery. This type of surgery was effective in removing these hard-to-reach tumors.
Treating my latest melanoma recurrence with immunotherapy and proton therapy
In July 2020, I was supposed to return to Houston for my check-up at MD Anderson. But due to COVID-19, I did not want to travel, so my MD Anderson care team allowed me to have scans done in South Carolina. On July 7, I had my PET/CT, MRI and endoscopic ultrasound. The results showed the tumors had returned. And one was eroding into my esophagus. I made plans to return to Houston for treatment. On July 15, I met with my care team at MD Anderson. They decided my best treatment option was a combination of pencil beam proton therapy and immunotherapy, which I now qualified for, thanks to research advances.
Finding hope during proton therapy at MD Anderson
I started proton therapy on July 27. I received 25 treatments to my esophagus. Proton therapy caused me the least amount of side effects of any treatment that I have had. Recovery from surgery may have been the hardest, but even that was short-term. Dr. Nguyen and the staff at the Proton Therapy Center helped make the treatments painless. Seeing the staff made my treatments an event that I looked forward to each day.
I had some mild discomfort when swallowing certain foods and juices following my proton therapy. I also experienced indigestion. To remedy this, I would take an antacid and eat softer foods. For me, the benefits of proton therapy outweigh any temporary discomforts.
My immunotherapy treatment
On July 24, I received two intravenous injections of the immunotherapy drug Keytruda.
I will continue this treatment every six weeks for the next two years. The only immunotherapy side effect I’ve experienced so far has been neuropathy.
I felt safe at MD Anderson during the COVID-19 pandemic
Though I’d initially avoided traveling to MD Anderson for my scans in early July, the precautions MD Anderson has taken to protect its patients from COVID-19 reassured me. Every employee and patient I saw wore a medical-grade face mask, and there were hand sanitizer stations everywhere.
As a survivor with reduced lung capacity, I am very conscious and aware of safety measures. That’s why I was thrilled that MD Anderson takes patient safety so seriously. Even the ancillary facilities, like the Rotary House, required visitors to wear masks and practice good hand hygiene.
I was also very happy to see MD Anderson limiting the number of people on its campus. That reduced my safety concerns even more.
Helping other cancer patients become survivors
When I first came to MD Anderson in 2014, I learned that I was a cancer survivor the day I was diagnosed. That has impacted my life in many ways.
MD Anderson has a wonderful mission of not just treating cancer, but ending cancer.
To support this mission, my wife and I created the Wilkes Family Cancer Autoimmune Research Fund in 2014. Our goal was to help make immunotherapy treatment an option for cancer patients with autoimmune diseases. We donated $1 million to support MD Anderson’s research into immunotherapies for autoimmune patients.
Now I advise other survivors not to harbor “Why me?” feelings. Instead, modify that to “Why not me?” I want to use the moment to bring hope, comfort and love to other survivors -- and to remind them to enjoy every second celebrating life.
Request an appointment at MD Anderson online or by calling 1-855-683-8523.
Related Cancerwise Stories

Instead of harboring ‘Why me?’ feelings, modify that to ‘Why not me!’
Bob Wilkes
Survivor